Biocon Pharma Limited’s facility at Bengaluru Concludes USFDA Surveillance and Inspection, With Zero Observations

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Karnataka, Bengaluru, India, June 03, 2023

This is to inform you that the USFDA concluded a surveillance and pre-approval inspection of Biocon Pharma Limited Oral Solid Dosage formulations manufacturing facility at Bengaluru on 2nd June 2023, with  no observations.